Efficacy and Safety of Two Short Standardised Regimens for the Treatment of Patients With Rifampicin-Resistant Tuberculosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial
Lancet Respir Med 2024 Oct 01;[EPub Ahead of Print], RL Goodall, AJ Nunn, SK Meredith, A Bayissa, AK Bhatnagar, CY Chiang, F Conradie, N Gopalan, M Gurumurthy, B Kirenga, N Kiria, D Meressa, R Moodliar, N Ngubane, M Rassool, K Sanders, R Solanki, SB Squire, M Teferi, G Torrea, B Tsogt, E Tudor, A Van Deun, ID RusenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.